VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc. (VRCA) is expected to report earnings on February 11, 2027, after the market close. The consensus earnings estimate is a loss of $0.72 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -23.2% since its last earnings release on November 12, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Verrica Pharmaceuticals Inc.
Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Verrica’s late-stage product candidate, VP-102, is in development to treat molluscum, common warts and external genital warts, three of the largest unmet needs in medical dermatology. Verrica is also developing VP-103, its second cantharidin-based product candidate, for the treatment of plantar warts. The Company has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatologic oncology conditions.
Sector
Healthcare
Industry
Drug Manufacturers/Other
Charts powered in part by Lightweight Charts™ by TradingView.